Paper Details

  1. Home
  2. Paper Details

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.

Author: , AhimbisibweGrace M, AliShabinah, AmugePauline, ArcharyMoherndran, AtwineLorna, Barlow-MoshaLinda, BbuyeDickson, BehuhumaOsee, BernaysSarah, Bwakura-DangarembiziMutsa, ChalermpantmetagulSuwalai, CoelhoAlexandra, ColbersAngela, CompagnucciAlexandra, CottonMark F, CresseyTim R, FordDeborah, GiaquintoCarlo, GibbDiana M, GrosseleTiziana, KaudhaElizabeth, KekitiinwaAdeodata R, KityoCissy M, KleinNigel, KobbeRobin, LibertyAfaaf, LugemwaAbbas, MakumbiShafic, MujuruHilda A, MusiimeVictor, MusokePhilippa, MusoroGodfrey, NgampiyaskulChaiwat, PuthanakitThanyawee, RamsagarNastassja, RojoPablo, SarfatiTatiana, SaïdiYacine, ShakeshaftClare, TurkovaAnna, VariavaEbrahim, ViolariAvy, WelchSteven B, WhiteEllen, WynneBen

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolutegravir-based antiretroviral treatment (ART) was superior to standard care in children and adolescents starting first- or second-line ART for HIV-1 infection. This open-label, randomized, noninferiority trial found that dolutegravir-based ART led to a lower proportion of participants experiencing virologic or clinical treatment failure while maintaining a similar safety profile.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Children with human immunodeficiency virus type 1 (HIV-1) infection have limited options for effective antiretroviral treatment (ART). METHODS: We conducted an open-label, randomized, noninferiority trial comparing three-drug ART based on the HIV integrase inhibitor dolutegravir with st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34965338

データ提供：米国国立医学図書館（NLM）

Dolutegravir: A Beacon of Hope for Children with HIV-1

For children living with HIV-1, the journey through treatment can be fraught with challenges, especially when finding effective medications. This [open-label, randomized, noninferiority trial] provides much-needed hope, comparing the effectiveness of a new antiretroviral treatment based on dolutegravir with the standard of care. The researchers recruited a large cohort of children and adolescents and followed them for over two years, carefully monitoring their viral load and clinical outcomes. This research, like a desert expedition mapping a new route, is paving the way for a more effective and well-tolerated treatment for children with HIV-1. The study found that dolutegravir-based therapy was significantly more effective than standard care in suppressing the virus, offering hope for a healthier future for these children.

A Turning Point in HIV-1 Treatment

Dolutegravir emerges as a powerful weapon in the fight against HIV-1, demonstrating its ability to effectively control viral load and improve treatment outcomes in children. This could represent a turning point in the management of pediatric HIV-1 infection.

A Brighter Future for Children with HIV-1

The study's findings are a beacon of hope, suggesting that children with HIV-1 can now benefit from a treatment that is both effective and well-tolerated. This opens the door to a brighter future for these children, allowing them to thrive and lead fulfilling lives.

Dr.Camel's Conclusion

The development of effective treatments for HIV-1 in children is a testament to the relentless pursuit of progress in medicine. Dolutegravir offers a new hope, offering a better chance for children with HIV-1 to live longer, healthier lives.

Date :
  1. Date Completed 2022-01-12
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

34965338

DOI: Digital Object Identifier

EMS175950

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.